Mountain Valley MD Provides Business Update, Advances Commercialization Strategies

Executive Summary

• Mountain Valley MD Holdings Inc. (MVMD) released a comprehensive business update detailing commercialization progress across its three core technology platforms: Nutraceuticals (Quicksome™), Agriculture (Agrarius™), and Husbandry/Aquatic (Soluvec™/Quicksol™).
• In Nutraceuticals, MVMD reported $193,000 in sales for licensee Circadian’s Quicksome™ products (April–June 2025) and is advancing business development with an MLM client for a testosterone formulation, with commercial terms anticipated in 2025.
• In Agriculture, MVMD presented significant yield increase data from field trials in Brazil for Agrarius™ across corn, sugarcane, soybeans, potatoes, and citrus, while expanding regulatory registrations and initiating new trials in Colombia and other crops.
• In Husbandry/Aquatic, MVMD highlighted the production of 200 tonnes of Soluvec™ 1% in Bangladesh, though royalty revenues remain below expectations due to cyclone damage; the company is accelerating expansion into Latin America and other emerging markets.

Key Details

• Nutraceuticals (Quicksome™):

  • Circadian Sales: Circadian Wellness Corp. reported USD $193,000 in sales for its "Eons Dialed" and "Eons Deeper Sleep" products during April to June 2025, a notable increase from prior periods.
  • MLM Partnership: MVMD is working with a U.S.-based multi-level marketing client on a novel fenugreek glycosides testosterone formulation. The product is a Quicksome™ quick-dissolve tablet with documented effects on testosterone levels. Commercial terms are anticipated in calendar 2025, with a white-label version planned for manufacturing in the current quarter.
  • Pipeline: Additional formulations for energy, lean metabolism, focus, stress, anxiety, hematological health, joint health, and pain management are available for manufacturing through the Lead Manufacturer.
  • Branding: The "Mountains Of…" proprietary brand has secured U.S. trademark protection for Sleep, Energy, Relief, Libido, and Lean categories.

• Agriculture (Agrarius™):

  • Brazil Field Trials (Corn): UNESP study showed a 14.8% yield increase in Dourados and 11.2% in Santa Cruz, with improved physiological conditions and chlorophyll concentrations.
  • Brazil Field Trials (Sugarcane): Agroquatro A.S. trials demonstrated an 8–12 tons/hectare yield improvement (~10%), a 15% increase in sugar yield, and a 47% reduction in pest damage.
  • Brazil Field Trials (Soybeans): 14 validation trials showed an average yield increase of 6.34 sacs/hectare. A CESB Competition participant achieved a 15.61% productivity gain (117.93 bags/ha vs. 102 bags/ha).
  • Brazil Field Trials (Potatoes): June 2025 harvest showed an 18.49% productivity increase (51,250 Kg/Ha vs. 43,250 Kg/Ha control).
  • Brazil Field Trials (Citrus): Preliminary results showed a 5.29% productivity increase; satellite data suggests up to 15% improvement.
  • New Trials: Commenced testing on cotton, coffee, and citrus; second cycle for sugarcane; and farmer-led validations for wheat and barley.
  • Colombia Program: Partnership with FEDEGAN (national cattle growers’ federation) to test grass productivity across 43 million hectares. Study runs through 2026 with preliminary results expected in 2025.
  • Regulatory & Logistics: Secured registration in Canada, Brazil, Colombia, Panama, Bolivia, Peru, and most US states. Filed trademarks in 13 LATAM jurisdictions. Completed first trial import/clearance into Brazil via Panama logistics partner.
  • Performance Guarantee Program (PGP): Central to go-to-market strategy; clients pay only after meeting performance thresholds. MVMD and Agrarius Corp. share risk, with AC deferring payment until obligations are met.

• Husbandry Animals/Aquatic (Soluvec™/Quicksol™):

  • Bangladesh Licensee Activity: As of July 2025, the licensee produced approximately 200 tonnes of Soluvec™ 1% coated fish feed, distributed through five local distributors.
  • Revenue Impact: Royalty revenues are below management’s expectations, partly due to damage from Cyclone Remal in 2024. MVMD has communicated performance concerns to the licensee.
  • Expansion Plans: MVMD intends to accelerate commercialization in Latin America and other emerging markets. Patent protection filed in 12 additional markets including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina, and Chile.
  • Product Stability: Soluvec™ 1% documented to have nine-month stability at room and refrigerated temperatures.

Notable Quotes

• Dennis Hancock, President & CEO: “In recent months, we have focused on measured execution across all business lines... We continue to advance the commercial foundations needed to bring our technologies to market at scale, supported by progress in field trials and product launches.”
• Dennis Hancock, President & CEO: “Our Quicksome™ technology has proven adaptable across multiple product formulations... We believe the platform’s dose-sparing benefits and demonstrated efficacy versus orally consumed competitors will continue to attract new partners and product opportunities in this scaled commercialization phase.”
• Dennis Hancock, President & CEO: “We believe the results of our collaboration with agronomists and agricultural partners throughout Latin America continue to validate the numerous Agrarius benefits across major crop types in diverse real-world conditions... We view being intentional with our data-driven approach as being the foundation for long-term adoption and meaningful commercial growth.”
• Dennis Hancock, President & CEO: “The results we are seeing from Agrarius trials in Latin America confirm to us its performance in diverse real-world conditions... Completing effective Agrarius trials helps build the confidence needed for larger agricultural operators to continue evaluating the impact of successfully integrating Agrarius more broadly into their operations.”
• Dennis Hancock, President & CEO: “The combination of consistent trial results, expanding regulatory approvals, and the Performance Guarantee Program is intended to position Agrarius for scaled adoption... We view these as the key steps that will move us from testing into commercial use.”
• Dennis Hancock, President & CEO: “Soluvec™ continues to demonstrate to us its measurable advantages in stability, bioavailability, and application. Our priority is to support the existing licensee in Bangladesh while advancing expansion into additional markets where our patents support strategic capital deployment.”